A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F, Wunderle L, Badura S, Schleyer E, Brüggemann M, Serve H, Schnittger S, Gökbuget N, Pfeifer H, Wagner S, Ashelford K, Bug G, Ottmann OG.
Lang F, et al. Among authors: ottmann og.
BMC Pharmacol Toxicol. 2020 Sep 29;21(1):70. doi: 10.1186/s40360-020-00446-x.
BMC Pharmacol Toxicol. 2020.
PMID: 32993794
Free PMC article.
Clinical Trial.